linjc16/ctgov huggingface dataset:
Benefits of Using a Transparent Visor to Replace the Face Mask in Speech Therapy Rehabilitation of Oral-Linguo-Facial Praxies in the Context of COVID-19: a Series of Cases

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to compare the effectiveness of the use of a transparent covering visor with that of the face mask, with or without the use of video sequences, for speech therapy rehabilitation of oral-linguo-facial praxies in the context of the COVID 19 epidemic.

Detailed Description
-----------------
Statistic analysis: single case experimental design (SCED) method.

Official Title
-----------------
Benefits of Using a Transparent Visor to Replace the Face Mask in Speech Therapy Rehabilitation of Oral-Linguo-Facial Praxies in the Context of COVID-19: a Series of Cases

Conditions
-----------------
Covid19, Oral-Linguo-Facial Praxies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged >= 18 years; Hospitalization for more than 2 weeks prior to enrollment in the adult post intensive care rehabilitation care unit (PICRU) of Raymond Poincaré hospital in Garches; With oral-linguo-facial praxis disorders whatever the cause; Has been informed and not in opposition to participation of the study. Exclusion Criteria: Patient with fever or any suspect symptom of a SARS-CoV2 infection; Planned discharge of hospital in 2 weeks; Patient with cognitive, phasic or vigilance disorders preventing to understand the study; Under guardianship or curator; Patient Under french AME scheme.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oral-Linguo-Facial Motricity Test |  | throughtout of the study, an average of 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral-Linguo-Facial praxies, Covid19, speech therapy rehabilitation
Anthropometric Angular Measurement to Determine Muscle Tonus in Patients With Peripheral Facial Paralysis

Study Overview
=================
Brief Summary
-----------------
The current study sought to determine the reliability of the rehabilitation protocol using the labial commissure angle (LCA) as an indicator of both muscle tonus and therapeutic success. The investigators hypothesized that this measurement would provide objective data regarding the efficacy of rehabilitation for these challenging patients.

Detailed Description
-----------------
CONTEXT AND OBJECTIVE: In cases of peripheral facial paralysis (PFP), diminished facial movements and their resultant cosmetic sequelae may have significant emotional repercussions, in addition to producing pronounced functional deficits. Abnormal muscle proprioception and deviation of the nasal-labial filter may also interfere with articulation of the labiodental and bilabial phonemes, thus diminishing speech intelligibility. In relation to stomatognathic functions, weakened labial occlusion decreases intraoral pressure, thereby hindering liquid retention in the buccal cavity and giving rise to vestibular stasis on the paralyzed side. The aim of this study was to evaluate the reliability of the labial commissure angle (LCA) as an anthropometric marker for objectively assessing changes in facial muscle tonus.

Official Title
-----------------
Anthropometric Angular Measurement to Determine Muscle Tonus in Patients With Peripheral Facial Paralysis

Conditions
-----------------
Peripheral Facial Paralysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age range between 20 and 70 years incomplete PFP (Degree IV) integral facial nerve (FN) Exclusion Criteria: systemic disease potentially aggravating the PFP (neurological, degenerative, endocrinological)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Peripheral Facial Paralysis (PFP)<br>Patients who are diagnosed with peripheral facial paralysis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Facial paralysis, Muscle tonus, Rehabilitation, Myofunctional, Stomatognathic system
The Success Rate of Cryotherapy Application in Primary Molars With Signs of Irreversible Pulpitis

Study Overview
=================
Brief Summary
-----------------
The study is designed as a randomized controlled trial with two parallel groups. Children aged 5-9 years with primary molars from suffered symptomatic signs of irreversible pulpitis will be randomly assigned into two groups. The first group (experimental group) will be injected with 4% articaine 1:100.000 epinephrine (inferior alveolar nerve block). For the second group, the mandibular second primary molars will be anesthetized using 4% articaine 1:100.000 epinephrine using inferior alveolar nerve block.

Official Title
-----------------
The Success Rate of Cryotherapy Application in Primary Molars With Signs of Irreversible

Conditions
-----------------
Pain, Procedural

Intervention / Treatment
-----------------
* Other: Cryotherapy
* Other: Traditional local anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children are classified as I or II according to ASA Presence of at least one mandibular primary molar with symptomatic signs of irreversible pulpitis Presence of at least two-thirds of the root length in periapical radiograph Exclusion Criteria: Unrestorable crowns Children with systemic, severe behavior or emotional problems Presence of gingival redness, swellings, fistulous of sinus tract Radiographic evidence of internal root resorption, pulp stones or calcifications, and/or bone radiolucency

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cryotherapy during inferior alveolar nerve block<br> | Other: Cryotherapy<br>* local anesthetic injection with articaine 4% 1:100,000 epinephrine then an application ice packs<br>|
| Active Comparator: Inferior alveolar nerve block<br> | Other: Traditional local anesthesia<br>* local anesthetic injection with articaine 4% 1:100,000 epinephrine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assessment | Wong Backer pain scale | up to 24 hours |
Effects of Lagenbone on Bone Mineral Density

Study Overview
=================
Brief Summary
-----------------
To study the effects of the herbal supplement Lagenbone on Bone Mineral Density

Detailed Description
-----------------
To study the effects of the herbal supplement Lagenbone on Bone Mineral Density. Lagenbone is a supplement based on the Chinese Herbal formula Gui Lu Er Xian Jiao.

Official Title
-----------------
Effects of Lagenbone on Improvements in Bone Mineral Density - A Pilot Study

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Dietary Supplement: Lagenbone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of osteoporosis Able to read and understand English Willing to receive routine DEXA scans and comply with supplement schedule Exclusion Criteria: Pregnant, lactating, or having gestational diabetes Diagnosed with comorbid conditions that they are taking medication for e.g. Acid reflux, Hashimoto's/Grave's Disease, Endometriosis, prostate, breast, uterine cancer, kidney disease, fibroids, psychological disorders Use of any medication known to interfere with bone mineral density Are taking any new medications/supplements/treatments/therapeutic exercise within the last two months for osteoporosis or bone density Involved in health-related litigation, claims Missing baseline visits Vegan or vegetarian Diagnosed with Alzheimer's or demonstrating onset of dementia

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lagenbone<br>Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months. | Dietary Supplement: Lagenbone<br>* Traditional Chinese medicine herbal formula<br>* Other names: Gui Lu Er Xian Jiao;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dual-energy x-ray absorptiometry (DXA)DEXA Scan | Dual-energy x-ray absorptiometry (DXA) or bone densitometry or Bone Density Scan | 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short Osteoporosis Quality of Life Questionnaire (ECOS16) | Short Osteoporosis Quality of Life Questionnaire | 15 months | 
| 36-item Short form survey (SF36) | 36-item Short form survey | 15 months | 
| Osteoporotic Quality of Life Questionnaire (OQLQ10) | Osteoporotic Quality of Life Questionnaire | 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chinese medicine, herbal medicine, osteoporosis, bone mineral density
Miltefosine for Brazilian Visceral Leishmaniasis

Study Overview
=================
Brief Summary
-----------------
Miltefosine will be administered to Brazilian patients with kala azar

Detailed Description
-----------------
Miltefosine will be administered to Brazilian patients with kala azar. Both pediatric and adult patients will be studied. Patients will be followed for 6 months.

Conditions
-----------------
Kala Azar

Intervention / Treatment
-----------------
* Drug: Miltefosine: initially 2.5 mg/kg/day for 28 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed (untreated) visceral leishmaniasis with symptomatic disease and visualization of amastigotes in tissue samples or a positive culture. Age: Group 1: 2 to 12 years; Group 2: 13 to 60 years Sex: male and female patients eligible (no effort to be made to balance the study for gender) Exclusion Criteria: Exclusion criteria Safety concerns: Thrombocyte count <30 x 109/l; Leukocyte count <1 x 109/l; Hemoglobin <5 g/100 ml; ASAT, ALAT, AP >3 times upper limit of normal range; Serum creatinine or BUN >1.5 times upper limit of normal range; Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary); Immunodeficiency or antibody to HIV; Severe protein and/or caloric malnutrition (Kwashiorkor, Marasmus); Any non-compensated or uncontrolled condition; Lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months. Lack of suitability for the trial: Negative bone marrow aspirate (smear); Any history of prior anti-leishmania therapy; Any condition which compromises ability to comply with the study procedures; Concomitant serious infection other than visceral leishmaniasis (this would include evidence of other conditions associated with splenomegaly such as schistosomiasis or malaria). Administrative reasons: Lack of ability or willingness to give informed consent (patient and/or parent / legal representative); Anticipated non-availability for study visits/procedures.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Miltefosine: initially 2.5 mg/kg/day for 28 days|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cure rate at 6 months |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cure rate at 1 month |  |  | 
| safety |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
miltefosine, kala azar, Brazil
Serum A.Actinomycetemcomitans Antibodies and Periodontitis

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to analyze the association between serum A.actinomycetemcomitans antibodies in patients with periodontitis. Furthermore, the objective was to determine if the periodontitis influenced serum IgG A.actinomycetemcomitans antibodies levels

Detailed Description
-----------------
53 patients with periodontitis and 48 healthy subjects (HS) were enrolled in the present study. Enrolled patients were examined and characterized for clinical and blood samples analysis and A.actinomycetemcomitans antibodies were expressed and evaluated enzyme-linked immunosorbent assay (ELISA) units (EU). The Spearman Correlation Test and Jonckheere-Terpstra Test were applied in order to assess the interdependence between serum IgG A.actinomycetemcomitans antibodies and clinical periodontal parameters.

Official Title
-----------------
Association Among Serum A.Actinomycetemcomitans Antibodies and Periodontitis

Conditions
-----------------
Periodontal Diseases

Intervention / Treatment
-----------------
* Other: observation of serum A.actinomycetemcomitans levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of at least 15 teeth CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm; Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs Presence of ≥40% sites with bleeding on probing (BOP) Exclusion Criteria: Intake of contraceptives Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study Status of pregnancy or lactation Previous history of excessive drinking Allergy to local anaesthetic Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Ages Eligible for Study
-----------------
Minimum Age: 34 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels | Other: observation of serum A.actinomycetemcomitans levels<br>* Analysis of serum A.actinomycetemcomitans levels<br>|
| Periodontitis<br>Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels | Other: observation of serum A.actinomycetemcomitans levels<br>* Analysis of serum A.actinomycetemcomitans levels<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Attachment Level | evaluation of changes in clinical attachment level | 1-year |
Oral Device Clinical Trial

Study Overview
=================
Brief Summary
-----------------
The investigators are studying the use of a new medical device developed at Nationwide Children's. This technology has been licensed and produced by Zotarix LLC, a medical device company. It is designed to aid in retraction and provide protection of the lips during surgery. The investigators are not recording any of your identifiable personal health information except for the surgery date. This device, called the LabraGuard is a sterile, soft medical grade silicone, and no alternative device with these exact protective properties exists, and the investigators are trying to learn more about how it performs in different age children.

Official Title
-----------------
Surgical Safety Device Use During Transoral Surgery

Conditions
-----------------
Tonsil Disease, Dental Diseases, Adenoid; Disorder (and Tonsils)

Intervention / Treatment
-----------------
* Device: LabraGuard


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 21 years of age and under Having a surgical procedure done through the mouth where the lips are at risk of injury Performed by attendings from either the Otolaryngology department or the Dental department. Subject/Subject's guardian provides consent to be in the study Exclusion Criteria: Allergy to silicone Unable to achieve good fit

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oral Safety Device<br>patients on which the device LabraGuard is used. | Device: LabraGuard<br>* Protection of the lips and the oral commissure during transoral procedures<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical Field Visibility | Surgeons level of visibility of the oropharynx on a scale of 1 to 10 | baseline |
Mental Healthcare in Older Adults With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
As in the general population, there is a gradual and steady increase in life expectancy of patients with schizophrenia. But this increase is at a smaller scale, with a rate of premature death that is still 2 to 3 times higher than that found in the general population. This excessive early mortality is explained by an overrepresentation of suicide deaths, but also a higher prevalence of somatic diseases, mainly cardiovascular. But today there are only very few epidemiological data on the mortality of patients with schizophrenia, including those aged over 60 years. What are the sociodemographic and clinical characteristics (psychiatric and somatic) of these schizophrenic elderly patients? Do they benefit from a somatic follow-up adequate and systematic? What are their levels of social independence and of quality of life? the answers these questions and the description of the offer of geriatric care and of psychiatric care currently provided by different sectors of psychiatry in France is an indispensable prerequisite for any project to improve the quality of life, state of health and mortality of older patients with schizophrenia.

Detailed Description
-----------------
Evaluate prospectively over 5 years, the rates and causes of mortality in a cohort of schizophrenic patients older than 60 years, followed by adult psychiatry sectors, compared to those patients matched for sex and age and monitored by the same sectors for a chronic psychiatric disorder other than schizophrenia

Official Title
-----------------
The Mortality and Its Associated Factors in Schizophrenia Patients Older Than 60 Years

Conditions
-----------------
Schizophrenia, Chronic Psychiatric Disorder

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women aged than 60 years with a diagnosis of schizophrenia, according to the DSM-IV criteria Men or women aged than 60 years with chronic psychiatric disorder other than schizophrenia Patients consenting to participate to the study Patients enrolled in the national healthcare insurance program Exclusion Criteria: -Disease affecting the central nervous system

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| schizophrenia<br> | Other: Data collection<br> <br> |
| chronic psychiatric disorder other than schizophrenia<br> | Other: Data collection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | Death of any causes | 5 years |